Blood cancer mystery: scientists hunt for clues to treatment success
NCT ID NCT05440838
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for adults with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis who are starting their first treatment. Researchers want to find out why some patients respond well to standard drugs while others do not. They will look at genetic and immune system factors to help doctors choose the best treatment from the start.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2023
- Expected to finish
-
Feb 2032
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis requiring first-line treatment with hydroxyurea or pegylated interferon.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis. * Indication for first-line treatment with hydroxyurea or pegylated interferon. * Consent to participate. * Affiliated to social security. Exclusion Criteria: * Previous treatment. * Other on-going malignancy, including overt myelofibrosis. * Other treatment such as phlebotomy solely, ruxolitinib, anagrelide, or pipobroman.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Essential thrombocythemia are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Chu Angers
RECRUITINGAngers, France
-
Chu Brest
RECRUITINGBrest, 29606, France
-
Chu Nantes
RECRUITINGNantes, 44093, France
-
Chu Poitiers
RECRUITINGPoitiers, 86021, France
-
Chu Rennes
RECRUITINGRennes, 35033, France
-
Chu Tours
RECRUITINGTours, 37044, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pens and vouchers: can small rewards boost participation in blood cancer research?
- Can a targeted drug hit the mark in Hard-to-Treat blood cancers?
- Can tailored chemotherapy tame leukemia in down syndrome?
- Can a new injection tame overactive blood cell production?
- Can a hormone mimic curb the need for bloodletting in a blood cancer?
- Can a Dual-Action pill tame bone marrow tumors?